Biotech Firms Report Q2 2025 Financial Results, Clinical Progress

Alector, Inc. reported strong progress in its late-stage clinical programs for neurodegenerative diseases, including the pivotal INFRONT-3 Phase 3 trial of latozinemab for frontotemporal dementia linked to GRN mutations, with topline data expected by mid-Q4 2025. The company also continues advancing its Alzheimer’s disease and brain carrier programs, supported by a robust cash position of $307.3 million, extending runway into the second half of 2027. AnaptysBio, Inc. disclosed positive Phase 2b data for rosnilimab in rheumatoid arthritis and completed enrollment in its ulcerative colitis trial, with top-line data anticipated in Q4 2025; the company also plans to initiate a Phase 1b trial for ANB033 in celiac disease. Financially, AnaptysBio reported $22.3 million in collaboration revenue and a net loss of $38.6 million for Q2 2025, showing improvement from the prior year, and expects a $75 million milestone from GSK related to Jemperli sales. Both companies emphasize their clinical pipeline advancement and strategic collaborations as key drivers for future growth and value creation. APA Corporation’s Q2 2025 results were announced but are unrelated to the biotech sector and were therefore excluded from this summary.